(NASDAQ: CGON) Cg Oncology's forecast annual revenue growth rate of 441.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Cg Oncology's revenue in 2026 is $2,174,000.On average, 16 Wall Street analysts forecast CGON's revenue for 2026 to be $2,803,633,717, with the lowest CGON revenue forecast at $0, and the highest CGON revenue forecast at $9,397,609,854. On average, 15 Wall Street analysts forecast CGON's revenue for 2027 to be $9,753,347,703, with the lowest CGON revenue forecast at $1,976,321,386, and the highest CGON revenue forecast at $22,213,852,373.
In 2028, CGON is forecast to generate $32,073,679,432 in revenue, with the lowest revenue forecast at $16,846,324,822 and the highest revenue forecast at $64,964,507,258.